Moomoo AI 已提取核心信息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the fourth quarter and fiscal year ended December 31, 2023, on February 8, 2024. The company announced a 4% increase in Q4 revenue to $1.12 billion compared to the same period in 2022, and a 2% decrease in annual revenue to $4.50 billion. Despite shipping 79 NovaSeq X instruments in Q4 and 352 in the fiscal year, Illumina experienced a GAAP diluted loss per share of $(1.11) for Q4 and $(7.34) for the fiscal year, which included significant goodwill and intangible impairments related to the GRAIL segment. Non-GAAP diluted earnings per share remained stable at $0.14 for Q4 and decreased to $0.86 for the fiscal year. Illumina also announced its intention to divest GRAIL, aiming to finalize terms by the end of Q2 2024, in compliance with the European Commission's divestiture order. The company's financial outlook for fiscal year 2024 anticipates approximately flat Core Illumina revenue compared to 2023 and a Core Illumina non-GAAP operating margin of around 20%.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the fourth quarter and fiscal year ended December 31, 2023, on February 8, 2024. The company announced a 4% increase in Q4 revenue to $1.12 billion compared to the same period in 2022, and a 2% decrease in annual revenue to $4.50 billion. Despite shipping 79 NovaSeq X instruments in Q4 and 352 in the fiscal year, Illumina experienced a GAAP diluted loss per share of $(1.11) for Q4 and $(7.34) for the fiscal year, which included significant goodwill and intangible impairments related to the GRAIL segment. Non-GAAP diluted earnings per share remained stable at $0.14 for Q4 and decreased to $0.86 for the fiscal year. Illumina also announced its intention to divest GRAIL, aiming to finalize terms by the end of Q2 2024, in compliance with the European Commission's divestiture order. The company's financial outlook for fiscal year 2024 anticipates approximately flat Core Illumina revenue compared to 2023 and a Core Illumina non-GAAP operating margin of around 20%.
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 于2024年2月8日公布了截至2023年12月31日的第四季度和财年的财务业绩。该公司宣布，与2022年同期相比，第四季度收入增长4％，至11.2亿美元，年收入下降2％，至45.0亿美元。尽管第四季度出货了79只NovaSeq X工具，在本财年出货了352种，但Illumina第四季度的GAAP摊薄后每股亏损为1.11美元，本财年度的摊薄后每股亏损为7.34美元，其中包括与GRAIL板块相关的重大商誉和无形减值。第四季度非公认会计准则摊薄后每股收益稳定在0.14美元，本财年降至0.86美元。Illumina还宣布打算剥离GRAIL，目标是根据欧盟委员会的剥离令，在2024年第二季度末之前敲定条款。该公司2024财年的财务展望预计，与2023年相比，Core Illumina的收入将基本持平，Core Illumina的非公认会计准则营业利润率约为20％。
DNA测序和基于阵列的技术领域的全球领导者Illumina, Inc. 于2024年2月8日公布了截至2023年12月31日的第四季度和财年的财务业绩。该公司宣布，与2022年同期相比，第四季度收入增长4％，至11.2亿美元，年收入下降2％，至45.0亿美元。尽管第四季度出货了79只NovaSeq X工具，在本财年出货了352种，但Illumina第四季度的GAAP摊薄后每股亏损为1.11美元，本财年度的摊薄后每股亏损为7.34美元，其中包括与GRAIL板块相关的重大商誉和无形减值。第四季度非公认会计准则摊薄后每股收益稳定在0.14美元，本财年降至0.86美元。Illumina还宣布打算剥离GRAIL，目标是根据欧盟委员会的剥离令，在2024年第二季度末之前敲定条款。该公司2024财年的财务展望预计，与2023年相比，Core Illumina的收入将基本持平，Core Illumina的非公认会计准则营业利润率约为20％。
有用
没用